Regenerative Medicine Market
Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogeneic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, CVD, Ophthalmology, Neurology), Region, Competition - Global Forecast to 2031
REGENERATIVE MEDICINE MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global regenerative medicine market is projected to grow from USD 23.90 billion in 2026 to USD 62.69 billion by 2031, at a CAGR of 21.3% during the forecast period. The market was valued at USD 20.52 billion in 2025. The global regenerative medicine market encompasses therapies and technologies designed to repair, replace, regenerate, or restore damaged or diseased cells, tissues, and biological functions. The market includes cell therapies, including stem cell therapies and CAR-T/cellular immunotherapies; gene therapies, including in vivo and ex vivo approaches; and tissue-engineered products. These therapies use autologous or allogeneic cells, genetic modification, viral and non-viral delivery technologies, biomaterials, scaffolds, and engineered tissues to address cancer, genetic disorders, hematological diseases, musculoskeletal conditions, neurological disorders, cardiovascular diseases, wound and dermatological conditions, and other indications. Key end users include hospitals and specialty treatment centers, pharmaceutical and biotechnology companies, and academic and research institutes. FDA's regenerative medicine framework similarly encompasses cell therapies, therapeutic tissue-engineering products, certain human cell/tissue products, and qualifying gene therapies.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 20.52 Billion
Current Market Size (2026): USD 23.90 Billion
Forecast Market Size (2031): USD 62.69 Billion
CAGR (2026–2031): 21.3% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for approximately 52.3% of the market in 2025.
Product Leader: Cell therapy accounted for approximately 47.6% of the market in 2025.
Fastest-Growing Therapeutic Area: Oncology is registering a CAGR of 22.3% during the forecast period. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Star players include Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), and Novartis AG (Switzerland), given their strong market share and product footprint.
Emerging market players include Bluebird Bio, Inc. (US), Mesoblast Ltd. (Australia), and Stempeutics Research Pvt. Ltd. (India), which have secured strong footholds in specialized niche areas.
The global regenerative medicine market is expanding steadily, driven by the growing demand for advanced therapeutic approaches, increasing investments in cell and gene therapy research and development, and rising adoption of innovative regenerative technologies across tissue repair, oncology, rare diseases, musculoskeletal disorders, cardiovascular diseases, and other chronic and debilitating conditions.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The global regenerative medicine market is expanding rapidly, driven by increasing approvals and commercialization of cell and gene therapies, growing adoption of CAR-T and other engineered cell therapies, advances in gene editing and vector technologies, and expansion of regenerative approaches beyond oncology into rare genetic, hematological, musculoskeletal, dermatological, and other diseases. The market is also being shaped by advances in allogeneic/off-the-shelf therapies, automated and scalable manufacturing, tissue engineering, biomaterials, and improved cell-processing technologies, alongside regulatory initiatives intended to facilitate development of regenerative therapies for serious diseases. FDA's current approved-product portfolio demonstrates the increasing breadth of commercial cellular, gene and tissue-engineered therapies.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Expanding clinical pipeline and increasing commercialization of regenerative therapies
-
Broadening therapeutic applications of regenerative medicine
Level
-
High treatment costs and reimbursement constraints
-
Long-term safety and durability uncertainties
Level
-
Allogeneic and iPSC-derived “off-the-shelf” cell therapies
-
Clinical translation of tissue engineering and 3D bioprinting
Level
-
Shortage of specialized manufacturing infrastructure and skilled personnel
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Expanding clinical pipeline and increasing commercialization of regenerative therapies
Expanding clinical pipelines and increasing approvals and commercialization of cell therapies, gene therapies, and tissue-engineered products are driving adoption of regenerative medicines across oncology, rare genetic disorders, hematological diseases, and other therapeutic areas.
Restraint: High treatment costs and reimbursement constraints
High treatment and manufacturing costs, coupled with complex and inconsistent reimbursement pathways, can restrict patient access and create affordability challenges for commercially available cell and gene therapies.
Opportunity: Allogeneic and iPSC-derived “off-the-shelf” cell therapies
The growing development of allogeneic and iPSC-derived off-the-shelf cell therapies offers opportunities to reduce reliance on patient-specific manufacturing, shorten treatment turnaround times, improve scalability, and potentially lower manufacturing costs.
Challenge: Shortage of specialized manufacturing infrastructure and skilled personnel
Complex cell and gene therapy manufacturing requires specialized GMP facilities, advanced processing and quality-control capabilities, and highly trained personnel, creating capacity and workforce constraints as clinical pipelines and commercial volumes expand.
REGENERATIVE MEDICINE MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Mayo Clinic evaluates and treats eligible patients with CAR-T cell therapies for relapsed or refractory hematologic malignancies, including B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, and multiple myeloma. Treatment involves collecting a patient’s T cells, genetically modifying and expanding them, and reinfusing them under specialist supervision. | Enables access to personalized cellular immunotherapy for patients whose disease has persisted or returned after conventional treatment. CAR-T cells are designed to recognize specific tumor antigens and can continue expanding in the body after infusion, supporting sustained anticancer activity in eligible patients. |
 |
Transplant centers use products such as HEMACORD, an allogeneic umbilical-cord-blood hematopoietic progenitor-cell therapy, for unrelated-donor transplantation in patients with inherited or acquired hematopoietic disorders or following myeloablative treatment. Administration is directed by physicians experienced in hematopoietic progenitor-cell transplantation. | Provides hematopoietic and immunologic reconstitution where an appropriate cord-blood unit is available, offering an additional donor-cell source for patients with blood cancers, inherited metabolic disorders, immune deficiencies, and other eligible hematopoietic diseases. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global regenerative medicine market is a highly interconnected ecosystem in which pharmaceutical and biotechnology companies, cell and gene therapy developers, academic and research institutions, hospitals, specialty treatment centers, CDMOs, and technology providers collaborate to develop, manufacture, and commercialize advanced therapies. Technology and manufacturing providers support the ecosystem through cell isolation and processing systems, gene-editing technologies, viral and non-viral vectors, bioreactors, biomaterials and scaffolds, analytical solutions, cryopreservation, and automated manufacturing platforms. CDMOs and specialized logistics providers support process development, GMP manufacturing, quality testing, cryogenic storage, transportation, and chain-of-identity and chain-of-custody requirements, particularly for personalized cell therapies. Regulatory authorities and healthcare systems establish evolving standards for product safety, efficacy, manufacturing consistency, long-term patient monitoring, reimbursement, and commercialization, driving greater standardization and scalability. Collectively, these stakeholders support the advancement of cell therapies, gene therapies, and tissue-engineered products across oncology, genetic and rare diseases, hematological disorders, musculoskeletal disorders, and other therapeutic applications.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Global Regenerative Medicine Market, by Product
In 2025, cell therapy products accounted for the largest market share, supported by the growing commercialization of CAR-T and other cell-based therapies, expanding clinical applications, and increasing adoption across oncology, hematological, musculoskeletal, and other disorders.
Global Regenerative Medicine Market, by Therapeutic Areas
In 2025, musculoskeletal disorders accounted for the largest market share, driven by the high burden of orthopedic and degenerative conditions and the growing use of regenerative approaches for cartilage, bone, tendon, and other musculoskeletal tissue repair and regeneration.
REGION
Asia Pacific to be fastest-growing market during forecast period
During the forecast period, Asia Pacific is expected to witness rapid growth in the regenerative medicine market, driven by increasing investments in cell and gene therapy, stem cell research, and translational medicine, along with the growing adoption of advanced regenerative technologies. The expansion of pharmaceutical and biotechnology research, clinical development capabilities, manufacturing infrastructure, and government initiatives supporting regenerative medicine further supports regional market growth.
REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX
In the global regenerative medicines market, Novartis is a star player, supported by its broad portfolio of cell and gene therapies and strong capabilities across research, clinical development, manufacturing, and commercialization. Its presence in oncology and other therapeutic areas, along with its focus on advanced therapies such as CAR-T cell therapy, strengthens its position in the regenerative medicines market. Organogenesis is an emerging leader, driven by its portfolio of advanced wound care and regenerative medicine products, including bioengineered and extracellular matrix-based therapies. Its focus on tissue regeneration, wound healing, and development of innovative biologic products positions the company to benefit from the growing adoption of regenerative medicine approaches.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Novartis AG (Switzerland)
- Sarepta Therapeutics, Inc. (US)
- Gilead Sciences, Inc. (US)
- Amgen Inc. (US)
- Johnson & Johnson (US)
- SMITH+NEPHEW (UK)
- MEDIPOST Co., Ltd. (Korea)
- JCR Pharmaceuticals Co., Ltd. (Japan)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | 20.52 Billion |
| Market Size in 2026 (Value) | 23.90 Billion |
| Market Forecast in 2031 (Value) | 62.69 Billion |
| Growth Rate | 21.3% |
| Years Considered | 2023–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: REGENERATIVE MEDICINE MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Evaluate the competitive positioning of key players in the regenerative medicine market | Benchmarked leading companies across cell therapy, gene therapy, tissue engineering, stem cell therapies, cell-based immunotherapies, product portfolios, R&D capabilities, manufacturing capabilities, clinical pipelines, geographic reach, and therapeutic-area focus | Identifies competitive gaps, technology differentiation opportunities, strategic partnerships, pipeline opportunities, and market positioning strategies |
| Assess high-growth regenerative medicine technologies and application opportunities | Evaluated growth potential across cell therapies, gene therapies, tissue engineering, stem cell-based therapies, cell-based immunotherapies, and emerging regenerative technologies across oncology, musculoskeletal disorders, dermatology & wound care, cardiovascular diseases, ophthalmology, neurology, and other applications | Supports investment prioritization, technology development, pipeline expansion, manufacturing strategies, and identification of high-potential therapeutic applications |
RECENT DEVELOPMENTS
- July 2026 : The European Commission approved Itvisma for children aged two years and older, adolescents, and adults with 5q SMA and a bi-allelic SMN1 mutation. It became the first gene-replacement therapy approved in the EU for this broad SMA population.
- February 2026 : Gilead received updated FDA approval for Yescarta (axicabtagene ciloleucel) prescribing information, removing the previous limitations of use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL).
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study involved four major activities in estimating the current size of the regenerative medicine market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the regenerative medicine market. The secondary sources used for this study include the Alliance for Regenerative Medicine (ARM), American Society for Cell Biology (ASCB), Centre for Commercialization of Regenerative Medicine (CCRM), European Society of Gene & Cell Therapy (ESGCT), National Center for Biotechnology Information (NCBI), Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global regenerative medicine market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
Note: Tiers are defined based on a company's total revenue. As of 2025, Tier 1 = >USD 1 Bn, Tier 2 = USD 500 Mn to USD 1 Bn, and Tier 3 <USD 500 Mn.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the regenerative medicine market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The major players in the industry and market have been identified through extensive primary and secondary research.
- The product and company revenues generated from the regenerative medicine business of players operating in the market have been determined through secondary research and primary analysis.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Regenerative Medicine Market: Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data were triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Regenerative medicine refers to a branch of medical science that focuses on repairing, replacing, or regenerating damaged or diseased cells, tissues, or organs to restore normal function. This field employs various approaches, including stem cell therapy, gene therapy, tissue engineering, and other advanced techniques, to promote the body's natural healing processes.
Key Stakeholders
- Regenerative medicine product manufacturing companies
- Healthcare service providers (including hospitals & specialty clinics)
- National and regional research boards and organizations
- Research & development organizations
- Clinical research organizations (CROs)
- Research laboratories & academic institutes
- Market research & consulting firms
Report Objectives
- To define, describe, and forecast the regenerative medicine market by product, therapeutic area, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall regenerative medicine market
- To provide detailed information about global product revenues
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America (U.S., Canada), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific), Latin America (Brazil, Rest of Latin America), and Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, pipeline products (Phase 3 Regenerative medicines clinical trial molecules), partnerships, agreements, collaborations, expansions, and strategic alliances
- To benchmark players within the market using the proprietary "Company Evaluation Matrix" framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company's specific needs. The following customization options are available for this report with additional effort:
- Product-Level Information
-
Country-wise Information:
- Analysis for additional countries (up to five)
-
Company Information:
- Detailed analysis and profiling of additional key market players across the globe.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Regenerative Medicine Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
- Canada Regenerative Medicine Market
- US Regenerative Medicine Market
- Germany Regenerative Medicine Market
- UK Regenerative Medicine Market
- France Regenerative Medicine Market
- Italy Regenerative Medicine Market
- Spain Regenerative Medicine Market
- China Regenerative Medicine Market
- Japan Regenerative Medicine Market
- India Regenerative Medicine Market
- South Korea Regenerative Medicine Market
- Australia Regenerative Medicine Market
- Brazil Regenerative Medicine Market
- Rest Of Europe Regenerative Medicine Market
- Rest Of Asia Pacific Regenerative Medicine Market
- Rest Of Latin America Regenerative Medicine Market
Growth opportunities and latent adjacency in Regenerative Medicine Market
Melinda
Dec, 2022
According to your study, what would be the expected growth rate in the Regenerative Medicine Market by 2030?.
Jeff
Dec, 2022
Based on Regenerative Medicine By Products segment, which products are expected to witness the highest growth rate in the future?.